...
首页> 外文期刊>Mayo Clinic Proceedings >Emerging Issues in Gram-Negative Bacterial Resistance: An Update for the Practicing Clinician
【24h】

Emerging Issues in Gram-Negative Bacterial Resistance: An Update for the Practicing Clinician

机译:革兰氏阴性细菌耐药性的新问题:执业医生的更新

获取原文
获取原文并翻译 | 示例
           

摘要

The rapid and global spread of antimicrobial-resistant organisms in recent years has been unprecedented. Although resistant gram-positive infections have been concerning to clinicians, the increasing incidence of antibiotic-resistant gram-negative infections has become the most pressing issue in bacterial resistance. Indiscriminate antimicrobial use in humans and animals coupled with increased global connectivity facilitated the transmission of gram-negative infections harboring extended-spectrum beta-lactamases in the 1990s. Carbapenemase-producing Enterobacteriaceae, such as those containing Klebsiella pneumoniae carbapenemases and New Delhi metallo-beta-lactamases, have been the latest scourge since the late 1990s to 2000s. Besides beta-lactam resistance, these gram-negative infections are often resistant to multiple drug classes, including fluoroquinolones, which are commonly used to treat community-onset infections. In certain geographic locales, these pathogens, which have been typically associated with health caree associated infections, are disseminating into the community, posing a significant dilemma for clinicians treating community-onset infections. In this Concise Review, we summarize emerging trends in antimicrobial resistance. We also review the current knowledge on the detection, treatment, and prevention of infection with these organisms, with a focus on the carbapenemase-producing gram-negative bacilli. Finally, we discuss emerging therapies and areas that need further research and effort to stem the spread of antimicrobial resistance. (C) 2015 Mayo Foundation for Medical Education and Research
机译:近年来,抗药性微生物在全球范围内迅速发展,这是前所未有的。尽管耐药性革兰氏阳性感染已引起临床医生的关注,但抗生素耐药性革兰氏阴性感染的发病率不断增加已成为细菌耐药性中最紧迫的问题。在人类和动物中滥用抗生素以及增加全球连通性,促进了1990年代带有广谱β-内酰胺酶的革兰氏阴性感染的传播。自1990年代末至2000年代以来,生产碳青霉烯酶的肠杆菌科细菌,例如含有肺炎克雷伯菌碳青霉烯酶和新德里金属β-内酰胺酶的肠杆菌科,是最近的祸害。除了对β-内酰胺的耐药性外,这些革兰氏阴性感染通常还对多种药物具有耐药性,包括氟喹诺酮类药物,它们通常用于治疗社区发作的感染。在某些地理区域中,这些通常与医疗保健相关的感染相关的病原体正在向社区传播,这给治疗社区感染的临床医生带来了巨大的困境。在本简明评论中,我们总结了抗菌素耐药性的新兴趋势。我们还将回顾有关检测,治疗和预防这些生物感染的最新知识,重点是产生碳青霉烯酶的革兰氏阴性杆菌。最后,我们讨论了新兴的疗法和需要进一步研究和努力以阻止抗菌素耐药性扩散的领域。 (C)2015年梅奥医学教育与研究基金会

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号